Search

Your search keyword '"Willekens, Barbara"' showing total 259 results

Search Constraints

Start Over You searched for: Author "Willekens, Barbara" Remove constraint Author: "Willekens, Barbara"
259 results on '"Willekens, Barbara"'

Search Results

3. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

4. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019

5. Global uncertainty in the diagnosis of neurological complications of SARS-CoV-2 infection by both neurologists and non-neurologists: An international inter-observer variability study

6. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

7. Management of patients with neurological diseases considering post‐pandemic coronavirus disease 2019 (COVID‐19) related risks and dangers — An updated European Academy of Neurology consensus statement.

9. Reliability and External Validity of Digital Passive Gait Tracking in MS (P6-6.008)

10. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

12. A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial

13. Autochthonous Cases of Tick-Borne Encephalitis, Belgium, 2020

14. The COVID-19 pandemic and neurology: A survey on previous and continued restrictions for clinical practice, curricular training, and health economics

15. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

18. Role of cytokines in predicting one-year mortality in non-traumatic spinal cord injury (NTCSI) patients in Uganda

23. A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSEBRAIN): study protocol for a multi-center randomized placebo controlled clinical trial.

24. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

26. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

27. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis

28. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

31. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019

32. Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA

33. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis

34. sj-docx-1-msj-10.1177_13524585231151951 – Supplemental material for Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

35. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

41. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

42. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

43. MOGAD : MOG-antistof-gerelateerde ziekte

45. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program

46. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease

Catalog

Books, media, physical & digital resources